Stryker Corp. v. National Union Fire Insurance Co.

842 F.3d 422, 2016 FED App. 0276p, 2016 U.S. App. LEXIS 20653
CourtCourt of Appeals for the Sixth Circuit
DecidedNovember 18, 2016
Docket15-1657/1664
StatusPublished
Cited by22 cases

This text of 842 F.3d 422 (Stryker Corp. v. National Union Fire Insurance Co.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Stryker Corp. v. National Union Fire Insurance Co., 842 F.3d 422, 2016 FED App. 0276p, 2016 U.S. App. LEXIS 20653 (6th Cir. 2016).

Opinion

OPINION

COLE, Chief Judge.

Stryker Corporation has been engaged in a longstanding row with XL Insurance America, Inc. (its commercial umbrella insurer) and TIG Insurance Company (its excess liability insurer). Fifteen years by our count. See Stryker Corp. v. XL Ins. Am., 576 Fed.Appx. 496 (6th Cir. 2014); Stryker Corp. v. XL Ins. Am., 735 F.3d 349 (6th Cir. 2012); Stryker Corp. v. Nat’l Union Fire Ins. Co., 681 F.3d 819 (6th Cir. 2012). That insurance-coverage dispute, in its current incarnation, requires us to interpret the “consent-to-settle” provision of an excess-liability policy. The district court thought that the insurance contract contained a latent ambiguity, construed the policy against TIG, and entered summary judgment for Stryker. But the'contract is not ambiguous, in any sense of the word, so we reverse. '

I.

Stryker is a medical technologies firm. In the late 1990s, it purchased a subsidiary of Pfizer, Inc. that made and sold orthopedic products. One of those products, an artificial knee joint called the Duracon Unicompartmental Knee (or “Uni-Knee” for short), turned out to be defective. These medical devices were sterilized using gamma rays, which caused ultra-high-molecular-weight polyethylene in the artificial knees to degrade and, if implanted past their five-year shelf-life, potentially fail. Due to an inventory oversight, a number of expired Uni-Knees were sold to hospitals and implanted in patients. As a result, in the early 2000s, Stryker was subject to over 70 individual product-liability claims and potentially obligated to cover Pfizer’s losses as well. See Stryker, 735 F.3d at 352-53.

Stryker turned to its insurers for relief from exposure. Two policies, effective during the year 2000, are relevant here: a “commercial umbrella” policy, issued by XL, and an “excess liability” policy, issued by TIG. The umbrella policy covered any “batch” of losses that Stryker became “legally obligated to pay by reason of liability imposed by law or assumed by the [i]n-sured ... because of [bjodily [ijnjury.” That policy was limited to $15 million, after a $2 million self-insured retention. The excess-liability policy followed form, kicked in after the umbrella policy was fully “exhausted,” and extended to Stryker’s “ultimate net loss ... in excess of all underlying insurance” up to $25 million.

. The insurance companies balked at Stryker’s request for defense and indemnification. In October 2001, XL denied coverage outright, arguing that the Uni-Knee claims were “known or suspected” prior to the inception of the policy, while TIG waited in the wings, hoping that its excess layer would not be implicated at all. Stryk *425 er, in turn, filed multiple lawsuits against XL and TIG in the Western District of Michigan. During the pendency of that protracted litigation, Stryker unilaterally settled all of its individual product-liability claims for $7.6 million and was separately adjudicated liable in the Southern District of New York for $17.7 million of Pfizer’s losses. See Stryker, 735 F.3d at 353-54; see also Pfizer, Inc. v. Stryker Corp., 348 F.Supp.2d 131, 159 (S.D.N.Y. 2004).

Stryker’s case against XL was' resolved over a decade later. In July 2012, we conclusively held that XL was obliged to “provide[ ] coveragé for the claims made against' Stryker in connection with [the defective] Uni-Knees.” Stryker, 735 F.3d at 356. With concrete figures in hand and its legal obligation apparent, XL decided to cover Stryker’s losses. But it did so in non-chronological order: XL paid out the larger Pfizer judgment first, exhausted the limits of its coverage, • and left Stryker’s individual product-liability claims on the table. See id. at 357 & n.3 (“[T]he general rule is that an insurer may pay claims in any order it chooses.”).

And so, one score was left' unsettled. In October 2013, back in the Western District of Michigan, Stryker filed a supplemental complaint against TIG, seeking to recover the remaining $7.6 million paid to settle its direct product-liability claims. TIG dispute ed its coverage obligation, raising a defense that was “unique to [its] policy.” Stryker, 681 F.3d at 825 & n.4. In TIG’s view, the direct Uni-Knee claims did not constitute “ultimate net loss” because Stryker failed to obtain “written consent” at the time the settlements were made. Section III.B of the policy defines “ultimate net loss” as “the amount of the principal sum, award or verdict actually paid or payable in cash in the settlement or satisfaction of claims for which the insured is liable, either by adjudication or compromise with the written consent of [TIG], after making proper deduction for all recoveries and salvages,”

Discovery ensued and ultimately, in July 2014, the parties filed cross-motions for summary judgment. Stryker claimed that the policy, as applied to the idiosyncratic facts of this case, is latently ambiguous: because XL satisfied the Pfizer judgment first (and exhausted its policy), Stryker was forced to present its direct settlements to TIG years after they were made. Relying on the testimony of TIG’s former claims adjusters and underwriters, Stryker argued that the excess-liability policy did not actually require “consent to the Uni-Knee settlements when they were made.” In response, TIG urged the court to apply the plain language of the policy, and disputed Stryker’s characterization of its former employees’ testimony.

In October 2014, the district court granted summary judgment to Stryker, concluding that the contract indeed contained a latent ambiguity. Stryker Corp. v. XL Ins. Co., 57 F.Supp.3d 823 (W.D. Mich. 2014). “On the one hand,” the court said, “the policy, as interpreted and applied by TIG’s own employees, does not require TIG’s consent to settlements entered into below the TIG layer.” Id. at 831. “[0]n the other hand,” it recognized, the policy’s plain language “does require consent if those settlements are [ultimately] offered to TIG for payment.” Id. Thus, in the court’s view, the term “claims” in the definition of ultimate net loss was “susceptible to more than one interpretation.” Id. Having found the term ambiguous, the court then construed the contract against TIG based on various policy rationales. Id. at 831-35. All in all, the district court found that Stryker’s claims were covered under the policy, TIG could muster no defenses to enforcement, and Stryker was entitled *426 to a grand total of $8.6 million in damages and interest.

This appeal and cross-appeal followed.

II.

We review the district court’s grant of summary judgment de novo. Hobart Corp. v. Waste Mgmt. of Ohio, Inc., 758 F.3d 757, 765 (6th Cir. 2014). Summary judgment is proper if “there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
842 F.3d 422, 2016 FED App. 0276p, 2016 U.S. App. LEXIS 20653, Counsel Stack Legal Research, https://law.counselstack.com/opinion/stryker-corp-v-national-union-fire-insurance-co-ca6-2016.